|
業務類別
|
-- |
|
業務概覽
|
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise andexperience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline ofearlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. |
| 公司地址
| 50 rue de Dijon, Daix, FRA, 21121 |
| 電話號碼
| +33 380447500 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.inventivapharma.com |
| 員工數量
| 77 |
| Mr. Andrew Obenshain |
Chief Executive Officer |
-- |
08/04/2026 |
| Mr. Jean Volatier |
Chief Financial Officer and Deputy General Manager |
美元 212.92K |
08/04/2026 |
| Dr. Jason A. Campagna, M.D.,PhD |
President, Research and Development and Chief Medical Officer |
-- |
08/04/2026 |
| Ms. Martine Zimmermann, Pharm.D. |
Executive Vice President, Regulatory Affairs and Quality Assurance |
美元 149.50K |
08/04/2026 |
|
|
| Dr. Mark Pruzanski, M.D. |
Chairman of the Board |
08/04/2026 |
| Dr. Annick Schwebig |
Independent Director |
08/04/2026 |
| Dr. Srinivas Akkaraju, M.D.,PhD |
Independent Director |
08/04/2026 |
| Mr. Heinz Christoph Maeusli |
Independent Director |
08/04/2026 |
| Mr. G. Andre Turenne |
Independent Director |
08/04/2026 |
| Ms. Renee Aguiar-Lucander |
Independent Director |
08/04/2026 |
|
|
|
|
